Cartesian Therapeutics
RNAC
Cartesian Therapeutics (RNAC) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- $0.50
- EPS estimate
- −$0.80
- EPS surprise
- +162.27%
- Revenue surprise
- −67.91%
- Revenue
- $298,000.00
- Revenue estimate
- $928,571.00
- Reported
- Aug 7, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 7, 2025 | −$0.80 | $0.50 | +162.27% | $298,000.00 | SEC |
| Q1 2025 | May 8, 2025 | −$0.70 | −$0.68 | +3.04% | $1.1M | SEC |
| Q3 2024 | Nov 7, 2024 | −$0.80 | −$1.13 | −40.95% | $387,000.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.86 | $0.54 | +162.58% | $33.3M | SEC |
| Q1 2024 | May 8, 2024 | −$0.89 | −$10.50 | −1086.44% | $5.8M | SEC |
| Q4 2023 | Mar 7, 2024 | −$0.90 | −$2.17 | −141.11% | $8.3M | SEC |
| Q3 2023 | Nov 13, 2023 | −$2.34 | −$1.35 | +42.31% | $5.9M | SEC |
| Q2 2023 | Aug 17, 2023 | −$3.60 | −$2.10 | +41.67% | $5.2M | SEC |
| Q1 2023 | May 4, 2023 | −$2.60 | −$4.20 | −61.54% | $5.9M | SEC |
| Q4 2022 | Mar 2, 2023 | −$2.17 | $1.20 | +155.30% | $16.8M | SEC |
| Q3 2022 | Nov 3, 2022 | −$0.17 | −$1.50 | −775.15% | $20.7M | SEC |
| Q2 2022 | Aug 4, 2022 | −$2.27 | $1.80 | +179.25% | $39.3M | SEC |
| Q1 2022 | May 5, 2022 | −$3.35 | $6.90 | +305.91% | $34.0M | SEC |
| Q4 2021 | Mar 10, 2022 | −$2.46 | $3.00 | +222.20% | $29.9M | SEC |
| Q3 2021 | Nov 9, 2021 | −$2.23 | −$4.80 | −115.38% | $24.4M | SEC |
| Q2 2021 | Aug 12, 2021 | −$3.51 | $0.00 | +100.00% | $19.7M | SEC |
| Q1 2021 | May 13, 2021 | −$3.65 | −$6.60 | −80.82% | $11.1M | SEC |
| Q4 2020 | Mar 11, 2021 | −$3.73 | −$4.20 | −12.64% | $12.0M | SEC |
| Q3 2020 | Nov 5, 2020 | $2.96 | −$2.70 | −191.31% | $4.6M | SEC |
| Q2 2020 | Aug 6, 2020 | $0.58 | −$7.50 | −1390.21% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Cartesian Therapeutics (RNAC) last report earnings?
Cartesian Therapeutics last reported on Aug 7, 2025, covering fiscal Q2 2025.
Did RNAC beat earnings estimates?
Yes. Cartesian Therapeutics reported EPS of $0.50 for Q2 2025 against a −$0.80 estimate — a 162.27% beat.
How much revenue did RNAC report last quarter?
Cartesian Therapeutics reported $298,000.00 in revenue for Q2 2025, against a consensus estimate of $928,571.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.